Linsen

Linsen Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the development of next-generation small molecule drugs for oncology and autoimmune diseases. The company leverages its expertise in medicinal chemistry and structural biology to target challenging proteins such as USP7, MALT1, and WRN helicase. Its lead candidate, LS-001, is a potent and selective USP7 inhibitor currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors. Linsen's broader pipeline includes programs targeting immune-oncology pathways and DNA damage response mechanisms. Supported by top-tier investors like Qiming Venture Partners and Eight Roads, the company aims to deliver transformative therapies to patients globally.